Working... Menu
Trial record 1 of 5 for:    ibrutinib TG
Previous Study | Return to List | Next Study

Ublituximab + Ibrutinib in Select B-cell Malignancies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02013128
Recruitment Status : Active, not recruiting
First Posted : December 17, 2013
Last Update Posted : February 27, 2019
Information provided by (Responsible Party):
TG Therapeutics, Inc.

No Study Results Posted on for this Study
  Recruitment Status : Active, not recruiting
  Actual Primary Completion Date : May 2018
  Estimated Study Completion Date : May 2019